
        <html>
        <head>
            <style>
                body { font-family: Arial, sans-serif; line-height: 1.6; margin: 20px; }
                h3 { color: #333; }
                .question { margin-bottom: 15px; }
                .options { margin-left: 20px; margin-bottom: 10px; }
                .solution { background: #f8f9fa; padding: 10px; border-left: 4px solid #007bff; }
                .credits { text-align: center; margin-top: 20px; font-size: 18px; }
                .rainbow-text { 
                    background: linear-gradient(90deg, red, orange, yellow, green, blue, indigo, violet); 
                    -webkit-background-clip: text; 
                    color: transparent; 
                    font-weight: bold; 
                }
            </style>
        </head>
        <body>
        
            <div class="question">
                <h3>Question No: 1</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>Which of the following when administered to patient does not impact passive immunity?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>IgA</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Toxoid</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Antitoxin</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Monoclonal antibody</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>Toxoids are <strong>inactivated toxins</strong> used as vaccines to stimulate <strong>active immunity</strong> by triggering the production of memory cells. Toxoids <strong>do not provide passive immunity</strong> as they require time to generate an immune response.</li>
<li><strong>IgA </strong>found in breast milk, <strong>IgA provides passive immunity</strong> to newborns by protecting mucosal surfaces. Contributes to short-term immunity for the recipient.</li>
<li>Toxoids are <strong>inactivated toxins</strong> used as vaccines to stimulate <strong>active immunity</strong> by triggering the production of memory cells. Toxoids <strong>do not provide passive immunity</strong> as they require time to generate an immune response.</li>
<li><strong>Antitoxin </strong>are preformed antibodies administered to neutralize toxins (e.g., for diphtheria or tetanus). They provide <strong>passive immunity</strong> by immediately countering the toxin.</li>
<li><strong>Monoclonal antibody</strong> are <strong>preformed, specific antibodies</strong> used to treat certain infections, cancers, or autoimmune conditions. They provide <strong>passive immunity</strong> by neutralizing pathogens or modulating immune responses.</li>
</ul>
<p><strong>Active immunity and passive immunity</strong></p>
<table style="border-collapse: collapse; width: 100%;" border="1">
<tbody>
<tr>
<td style="width: 26.0791%;" width="165">
<p>&nbsp;</p>
</td>
<td style="width: 35.0719%;" width="246">
<p><strong>Active Immunity</strong></p>
</td>
<td style="width: 38.8489%;" width="274">
<p><strong>Passive Immunity</strong></p>
</td>
</tr>
<tr>
<td style="width: 26.0791%;" width="165">
<p>Means of acquisition</p>
</td>
<td style="width: 35.0719%;" width="246">
<p>Exposure to foreign antigens</p>
</td>
<td style="width: 38.8489%;" width="274">
<p>Receiving preformed antibodies</p>
</td>
</tr>
<tr>
<td style="width: 26.0791%;" width="165">
<p>Onset</p>
</td>
<td style="width: 35.0719%;" width="246">
<p>Very slow</p>
</td>
<td style="width: 38.8489%;" width="274">
<p>Very rapid</p>
</td>
</tr>
<tr>
<td style="width: 26.0791%;" width="165">
<p>Duration</p>
</td>
<td style="width: 35.0719%;" width="246">
<p>Long-lasting protection (memory)</p>
</td>
<td style="width: 38.8489%;" width="274">
<p>Short span of antibodies, like half-life = 3 weeks</p>
</td>
</tr>
<tr>
<td style="width: 26.0791%;" width="165">
<p>Examples</p>
</td>
<td style="width: 35.0719%;" width="246">
<p>Natural infection, vaccines, toxoid</p>
</td>
<td style="width: 38.8489%;" width="274">
<p>Antitoxin, maternal IgG crossing placenta, IgA in breast milk, humanized monoclonal antibody</p>
</td>
</tr>
</tbody>
</table>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 2</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong><strong>Which of the following are vaccine preventable cancer?</strong></strong></p>
<ol>
<li>HCC</li>
<li>Cervical cancer</li>
<li>Burkitt lymphoma</li>
<li>Merkel carcinoma</li>
</ol>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>1, 3, 4 are correct</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>1, 2 and 4 are correct</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>1 and 2 are correct</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>All are correct</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li><strong>Hepatocellular carcinoma (HCC)</strong>: Chronic infection with hepatitis B virus (HBV) is a major cause of HCC. The HBV vaccine effectively prevents HBV infection, reducing the risk of HCC.</li>
<li><strong>Cervical cancer</strong>: Persistent infection with high-risk types of human papillomavirus (HPV), particularly HPV-16 and HPV-18, is the leading cause of cervical cancer. HPV vaccines, such as the quadrivalent and nonavalent vaccines, provide protection against these high-risk strains, thereby preventing cervical cancer.</li>
<li><strong>Burkitt lymphoma</strong>: Although Burkitt lymphoma is associated with Epstein-Barr virus (EBV) infection, there is no approved vaccine to prevent EBV, and thus this cancer is not vaccine-preventable.</li>
<li><strong>Merkel carcinoma</strong>: Merkel cell carcinoma is associated with Merkel cell polyomavirus, but there is no vaccine available for this virus, making it non-preventable by vaccination.</li>
</ul>
<p><strong>Table: Microbial Carcinogenesis</strong></p>
<table style="border-collapse: collapse; width: 100%;" border="1">
<tbody>
<tr>
<td style="width: 17.6259%;" width="98">
<p>&nbsp;</p>
</td>
<td style="width: 16.9065%;" width="103">
<p><strong>Organism </strong></p>
</td>
<td style="width: 12.7698%;" width="76">
<p><strong>Gene</strong></p>
</td>
<td style="width: 25%;" width="246">
<p><strong>Mechanism</strong></p>
</td>
<td style="width: 27.6978%;" width="195">
<p><strong>Tumor</strong></p>
</td>
</tr>
<tr>
<td style="width: 17.6259%;" width="98">
<p><strong>Bacteria</strong></p>
</td>
<td style="width: 16.9065%;" width="103">
<p><em>H. pylori</em></p>
</td>
<td style="width: 12.7698%;" width="76">
<p>Cag-A</p>
</td>
<td style="width: 25%;" width="246">
<p>Growth factor stimulation</p>
</td>
<td style="width: 27.6978%;" width="195">
<p>Gastric&nbsp; adenocarcinomas and gastric MALToma</p>
</td>
</tr>
<tr>
<td style="width: 17.6259%;" rowspan="2" width="98">
<p><strong>Oncogenic RNA Viruses</strong></p>
</td>
<td style="width: 16.9065%;" width="103">
<p>HTLV&ndash;1</p>
</td>
<td style="width: 12.7698%;" width="76">
<p>Tax</p>
</td>
<td style="width: 25%;" width="246">
<p>Increased pro-growth signaling and cell survival and genomic instability</p>
</td>
<td style="width: 27.6978%;" width="195">
<p>Adult T cell leukemia/ Lymphoma</p>
</td>
</tr>
<tr>
<td style="width: 16.9065%;" width="103">
<p>Hep C</p>
</td>
<td style="width: 12.7698%;" width="76">
<p>HCV core protein</p>
</td>
<td style="width: 25%;" width="246">
<p>Activates growth-promoting signal transduction pathways</p>
</td>
<td style="width: 27.6978%;" width="195">
<p>Hepatocellular carcinoma</p>
</td>
</tr>
<tr>
<td style="width: 17.6259%;" rowspan="6" width="98">
<p><strong>Oncogenic DNA Viruses</strong></p>
</td>
<td style="width: 16.9065%;" rowspan="2" width="103">
<p>HPV</p>
<p>Low risk (6,11)</p>
<p>High risk (16,18)</p>
</td>
<td style="width: 12.7698%;" width="76">
<p>E6</p>
</td>
<td style="width: 25%;" width="246">
<p>Degradation of p53Q and stimulation of TERT</p>
</td>
<td style="width: 27.6978%;" rowspan="2" width="195">
<p><strong>Low risk:</strong> Genital warts</p>
<p><strong>High risk:</strong> Squamous cell Ca cervix, Ca Oropharynx, anus, head/neck (laryngeal papilloma), esophagus</p>
</td>
</tr>
<tr>
<td style="width: 12.7698%;" width="76">
<p>E7</p>
</td>
<td style="width: 25%;" width="246">
<p>Inactivates RBQ and CDKI (p21 and p27)</p>
</td>
</tr>
<tr>
<td style="width: 16.9065%;" rowspan="3" width="103">
<p>EBV (Epstein&ndash;Barr virus)</p>
</td>
<td style="width: 12.7698%;" width="76">
<p>LMP1</p>
</td>
<td style="width: 25%;" width="246">
<p>Activates NF-kB and JAK/STAT pathway</p>
</td>
<td style="width: 27.6978%;" rowspan="3" width="195">
<p><strong>Lymphoma:</strong> Burkitt&rsquo;s, Hodgkin, T-cell and NK cell</p>
<p><strong>Carcinoma:</strong> Nasopharyngeal and gastric</p>
<p>&nbsp;</p>
</td>
</tr>
<tr>
<td style="width: 12.7698%;" width="76">
<p>EBNA2</p>
</td>
<td style="width: 25%;" width="246">
<p>Activates cyclin D</p>
</td>
</tr>
<tr>
<td style="width: 12.7698%;" width="76">
<p>vIL-10</p>
</td>
<td style="width: 25%;" width="246">
<p>B cell activation</p>
</td>
</tr>
<tr>
<td style="width: 16.9065%;" width="103">
<p>Hep B</p>
</td>
<td style="width: 12.7698%;" width="76">
<p>HBx</p>
</td>
<td style="width: 25%;" width="246">
<p>Activates transcription factors</p>
</td>
<td style="width: 27.6978%;" width="195">
<p>Hepatocellular carcinoma</p>
</td>
</tr>
</tbody>
</table>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 3</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>Which of the following is not a live vaccine?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Rotavirus vaccine</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Measles vaccine</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Hepatitis B vaccine</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Varicella vaccine</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>Table:</strong> Types of vaccine and their viral and bacterial infections</p>
<table style="border-collapse: collapse; width: 100%;" border="1">
<tbody>
<tr>
<td style="width: 25%;" width="139">
<p><strong>Vaccine </strong></p>
</td>
<td style="width: 26.6187%;" width="224">
<p><strong>&nbsp;&nbsp;&nbsp; Viral </strong></p>
</td>
<td style="width: 30.5755%;" width="253">
<p><strong>&nbsp; Bacterial </strong></p>
</td>
<td style="width: 17.8058%;" width="101">
<p><strong>Rickettsial </strong></p>
</td>
</tr>
<tr>
<td style="width: 25%;" width="139">
<p><strong>Live attenuated </strong></p>
</td>
<td style="width: 26.6187%;" width="224">
<p>Polio (OPV/Sabin), Yellow fever</p>
<p>Measles, Mumps, Rubella,</p>
<p>Influenza, JE (SA 14-14-2)</p>
<p>Varicella, Rotavirus</p>
</td>
<td style="width: 30.5755%;" width="253">
<p>BCG,</p>
<p>Typhoid (oral) Plague</p>
</td>
<td style="width: 17.8058%;" width="101">
<p>Epidemic typhus</p>
</td>
</tr>
<tr>
<td style="width: 25%;" width="139">
<p><strong>Killed </strong></p>
</td>
<td style="width: 26.6187%;" width="224">
<p>Polio (Salk/IPV), KFD, Influenza, Hepatitis B and A, Japanese encephalitis, Rabies</p>
</td>
<td style="width: 30.5755%;" width="253">
<p>Typhoid (IM), Plague, Cholera,</p>
<p>Pertussis, Cerebrospinal Meningitis</p>
</td>
<td style="width: 17.8058%;" width="101">
<p>Typhus</p>
</td>
</tr>
<tr>
<td style="width: 25%;" width="139">
<p><strong>Toxoid </strong></p>
</td>
<td style="width: 26.6187%;" width="224">
<p>&nbsp;</p>
</td>
<td style="width: 30.5755%;" width="253">
<p>Diphtheria, Tetanus, Anthrax</p>
</td>
<td style="width: 17.8058%;" width="101">
<p>&nbsp;</p>
</td>
</tr>
<tr>
<td style="width: 25%;" width="139">
<p><strong>Prote<u>i</u>n </strong></p>
</td>
<td style="width: 26.6187%;" width="224">
<p>&nbsp;</p>
</td>
<td style="width: 30.5755%;" width="253">
<p>Acellular Pertussis, Influenza (HA and NA)</p>
</td>
<td style="width: 17.8058%;" width="101">
<p>&nbsp;</p>
</td>
</tr>
<tr>
<td style="width: 25%;" width="139">
<p><strong>Polysaccharides </strong></p>
</td>
<td style="width: 26.6187%;" width="224">
<p>&nbsp;</p>
</td>
<td style="width: 30.5755%;" width="253">
<p>Pneumococcal vaccine,</p>
<p>Meningococcal vaccine,</p>
<p>Typhoid (Vi), Hib</p>
</td>
<td style="width: 17.8058%;" width="101">
<p>&nbsp;</p>
</td>
</tr>
<tr>
<td style="width: 25%;" width="139">
<p><strong>Recombinant </strong></p>
</td>
<td style="width: 26.6187%;" width="224">
<p>Hepatitis B, HPV</p>
</td>
<td style="width: 30.5755%;" width="253">
<p>Cholera Toxin B, Lyme disease</p>
</td>
<td style="width: 17.8058%;" width="101">
<p>&nbsp;</p>
</td>
</tr>
</tbody>
</table>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 4</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>Vaccine that should not be given in age above 65 years is:</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Herpes zoster vaccine</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Human Papilloma virus</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Pneumococcal vaccine</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Influenza vaccine</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>The <strong>HPV vaccine</strong> is not recommended for individuals <strong>above 65 years of age</strong>, as it does not provide significant benefit at this stage of life.</li>
<li>The <strong>recommended age group</strong> for HPV vaccination is:</li>
<li><strong>Routine:</strong> 11&ndash;12 years (can start as early as 9 years).</li>
<li><strong>Catch-up vaccination:</strong> For individuals up to <strong>26 years of age</strong> who missed earlier vaccination.</li>
<li>For individuals <strong>above 26 years (27-45 years</strong>) can recommend HPV vaccination based on shared clinical decision-making.</li>
</ul>
<p><strong>Table: Recommended Adult Immunization Schedule by Age Group</strong></p>
<p><strong><img title="2.jpg" src="https://static.pw.live/5eb393ee95fab7468a79d189/ADMIN/ea10b5c1-e287-4ebd-a53f-94eec16212b2.jpg" alt="" width="500" height="329" /></strong></p>
<ul>
<li>Any one of quadrivalent high-dose inactivated influenza vaccine (HDIIV4), quadrivalent recombinant influenza vaccine (RIV4), or quadrivalent adjuvanted inactivated influenza vaccine (aIIV4) is preferred in age 65 years or older. If none of these three vaccines are available, then any other age-appropriate influenza vaccine should be used.</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 5</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>Which vaccine will be placed at zone 3 in the device shown below?</strong></p>
<p><strong><img title="3.jpg" src="https://static.pw.live/5eb393ee95fab7468a79d189/ADMIN/ac23ab1d-2403-4c52-8808-6277b74186ee.jpg" alt="" width="196" height="187" /></strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Pentavalent</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Hep B</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>OPV</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>DPT</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>The image shown in the question is of an <strong>ice-lined refrigerator (ILR</strong>). The OPV vaccines are stored in the zone 3 that corresponds to the lowest.</li>
<li>ILRs are the main method of <strong>vaccine storage</strong> in <strong>primary health centers</strong>. They are an important part of the cold chain and they maintain a temperature of <strong>2&deg;C to 8&deg;C</strong> for the storage of vaccines.</li>
<li>They have different temperature zones for different vaccines. The <strong>upper zone</strong> is for <strong>freeze-sensitive vaccines</strong> like cholera, Hep B, rotavirus (liquid), etc. while the <strong>lower zone</strong> is for <strong>heat-sensitive vaccines</strong> like OPV, measles, etc.</li>
<li>All vaccines are kept in the basket provided with ILR. Vaccines like OPV, BCG, measles, and JE can be kept at the bottom of the basket while, DPT, TT, Hep B, IPV, and pentavalent vaccines and diluents are kept in the upper part of the basket.</li>
</ul>
<p><img title="4.jpg" src="https://static.pw.live/5eb393ee95fab7468a79d189/ADMIN/a67805c6-b2b2-45b3-9eb4-01867d85b608.jpg" alt="" width="258" height="245" /> <img title="5.jpg" src="https://static.pw.live/5eb393ee95fab7468a79d189/ADMIN/900bc88c-c5a9-48c3-8802-f14ea3c48f40.jpg" alt="" width="263" height="170" /></p>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 6</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>Pick the correct statement regarding the Sanchol cholera vaccine:</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Bivalent vaccine given in 2 liquid doses orally to children &gt;=1 year of age</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Bivalent given in single dose orally to children &gt;1 year of age</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Monovalent given in 2 liquid doses orally with a bicarbonate buffer</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Monovalent given in a single dose orally with a bicarbonate buffer</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>The Sanchol cholera vaccine is a <strong>bivalent vaccine</strong> given in 2 liquid doses orally to children &gt;=1 year of age.</li>
<li>The <strong>Sanchol cholera</strong> vaccine is a <strong>bivalent oral cholera vaccine (OCV)</strong> that targets both <strong>Vibrio cholerae O1</strong> and <strong>Vibrio cholerae O139</strong> serogroups, which are the primary causes of cholera outbreaks. It is designed to provide immunity by <strong>stimulating</strong> the production of <strong>antibodies</strong> in the <strong>intestines,</strong> the site of infection.</li>
</ul>
<p><strong>Key Features of the Sanchol Vaccine:</strong></p>
<ul>
<li>Bivalent Nature: The vaccine protects against two strains of the cholera bacterium: O1, which is responsible for most global cholera cases, and O139 which is seen in <strong>South Asia. </strong></li>
<li><strong>Dosing Schedule:</strong> The Sanchol vaccine is administered in <strong>two oral doses</strong>. The doses are given <strong>14 day</strong>s apart for children aged 1 year and above as well as This <strong>two-dose</strong> regimen is essential for achieving <strong>effective immunity</strong>. The vaccine is provided in <strong>liquid form</strong>, making it easy to administer. It does not require any special preparation, such as mixing with a bicarbonate buffer, which is needed for some older cholera vaccines.</li>
<li><strong>Age Recommendation:</strong> The vaccine is recommended for individuals aged <strong>1 year</strong> and It is particularly useful in <strong>endemic regions</strong> or during <strong>outbreaks</strong> to prevent the spread of the disease.</li>
<li><strong>Efficacy and Duration:</strong> Sanchol has been shown to provide significant protection against cholera for up to <strong>3-5 years</strong> after vaccination, although <strong>booster doses</strong> may be required in areas with <strong>ongoing</strong></li>
<li>The vaccine is widely used in <strong>mass vaccination campaigns</strong>, especially in <strong>areas prone</strong> to <strong>cholera outbreaks</strong>, such as <strong>refugee camps</strong> or regions with <strong>poor sanitation</strong>. It has been a critical tool in reducing the incidence of cholera in many endemic areas.</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 7</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>Which of the following statements is incorrect about rotavirus vaccine?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Available as monovalent and pentavalent vaccines</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>It is a subunit vaccine</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Not recommended after 6 months of age</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Oral route of administration</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>Rotavirus vaccine <strong>is not a subunit vaccine</strong>.</li>
<li>Rotavirus vaccines are <strong>oral, live attenuated</strong> vaccines and are of 3 types:
<ul>
<li><strong>Rotarix</strong> (human <strong>monovalent</strong>) vaccine is administered in 2 oral doses:
<ul>
<li>First dose: At 6 weeks, no later than 12 weeks (due to the risk of intussusception).</li>
<li>Second dose: With a gap of 4 weeks from the first dose, to be given by 16 weeks and <strong>no later than 24 weeks.</strong></li>
</ul>
</li>
<li><strong>RotaTeq</strong> (<strong>pentavalent</strong> bovine-human reassortant) vaccine is administered in <strong>3 oral doses</strong> at 2, 4, and 6 months. The first dose is given between 6-12 weeks and subsequent doses within a 4-10 weeks&rsquo; gap. All the 3 doses should be <strong>given before 32 weeks</strong>.</li>
<li><strong>Rotavac</strong> (monovalent liquid frozen) vaccine is administered in <strong>3 oral doses</strong>, 4 weeks apart at 6,10 and 14 weeks. It should <strong>not</strong> be administered to children <strong>more than 8 months</strong> of age.</li>
</ul>
</li>
<li><strong>Option C:</strong> According to the <strong>MoHFW</strong>, the rotavirus virus vaccine can be given till the <strong>age of 1 year</strong> and the potential benefit from vaccination outweighs the risk of intussusception. However, per the <strong>CDC guidelines</strong>, the maximum age for all rotavirus vaccines is <strong>8 months, 0 days</strong>. Since this is a recall question, the options appeared as such in the exam. Additionally, rotavirus is a live vaccine, making option b (which states that it is a subunit vaccine) the distinctly wrong statement and the better answer.</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 8</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>Which of the following is not a polysaccharide vaccine?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Pneumococcal</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Meningococcal</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Hepatitis B</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Haemophilus influenza type B</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>Hepatitis B vaccine is a <strong>recombinant protein vaccine</strong>.</li>
<li><strong>Polysaccharide vaccines</strong> are a type of subunit vaccine containing the capsular polysaccharide antigen. They generate a T-cell independent response.</li>
<li><strong>Examples include:</strong>
<ul>
<li>Pneumococcus</li>
<li>Meningococcus</li>
<li>Haemophilus influenzae type b (Hib)</li>
</ul>
</li>
<li><strong>Recombinant protein vaccines: </strong>With the help of recombinant DNA technology, the purified recombinant proteins from the cultured microorganisms result in cleaner vaccine preparations with a better safety profile.</li>
<li><strong>Examples include:</strong>
<ul>
<li>HBV</li>
<li>HPV</li>
<li>Lyme disease</li>
<li>Cholera Toxin-B</li>
<li>COVID-19</li>
</ul>
</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 9</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>A child came for DPT vaccination at 10 weeks. He has a history of fever of more than 40&deg;C and an inconsolable cry at 6 weeks of age following vaccination. What should be done next?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Avoid DPT vaccination</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Give DT vaccine</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Give DPT vaccine</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Defer by 4 weeks</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>The next step for this patient should be to administer <strong>DPT vaccine</strong>.</li>
<li>Events such as <strong>persistent inconsolable crying</strong> (more than <strong>3 hours</strong> in duration), <strong>hyperpyrexia </strong>(fever &gt; 40&deg;C), <strong>hypotonic-hyporesponsive episodes</strong> within 48 hours of DTwP administration, and seizures, with or without fever, within 72 hours DTwP administration are considered precautions <strong>but not contraindications to future doses of DTwP</strong>. These events <strong>don't recur</strong> with the next dose and have been shown to have no permanent sequelae.</li>
<li><strong>Absolute contraindications</strong> to any pertussis vaccination are a <strong>history of anaphylaxis</strong> or <strong>development of encephalopathy</strong> within 7 days following previous DTwP vaccination. In case of <strong>anaphylaxis</strong>, further immunization with <strong>diphtheria, tetanus, and pertussis vaccines are contraindicated</strong> as it cannot be said with certainty which component caused anaphylaxis. For patients with a history of <strong>encephalopathy </strong>following vaccination, any <strong>pertussis vaccine is contraindicated</strong>, and only <strong>diphtheria and tetanus vaccines</strong> may be <strong> </strong></li>
</ul>
<p><strong>Note:</strong> This answer might be controversial. The above answer is as per the IAP Guidebook on Immunization.</p>
<p><strong>Table: Adverse Events Following Immunization </strong></p>
<table style="border-collapse: collapse; width: 100%;" border="1">
<tbody>
<tr>
<td style="width: 24.2806%;" width="141">
<p><strong>Vaccine</strong></p>
</td>
<td style="width: 33.8129%;" width="274">
<p><strong>Common, Minor Reactions</strong></p>
</td>
<td style="width: 42.0863%;" width="312">
<p><strong>Rare, Serious Reactions</strong></p>
</td>
</tr>
<tr>
<td style="width: 24.2806%;" width="141">
<p>BCG</p>
</td>
<td style="width: 33.8129%;" width="274">
<p>Local pain and swelling</p>
</td>
<td style="width: 42.0863%;" width="312">
<p>Suppurative lymphadenitis</p>
<p>BCG Osteitis</p>
<p>Disseminated BCG infection</p>
</td>
</tr>
<tr>
<td style="width: 24.2806%;" width="141">
<p>Hepatitis B</p>
</td>
<td style="width: 33.8129%;" width="274">
<p>Local reaction, fever</p>
</td>
<td style="width: 42.0863%;" width="312">
<p>Anaphylaxis</p>
</td>
</tr>
<tr>
<td style="width: 24.2806%;" width="141">
<p>Inactivated influenza</p>
</td>
<td style="width: 33.8129%;" width="274">
<p>Local reaction</p>
</td>
<td style="width: 42.0863%;" width="312">
<p>Guillain-Barre syndrome (GBS)</p>
<p>Oculo-respiratory syndrome</p>
<p>Anaphylaxis</p>
</td>
</tr>
<tr>
<td style="width: 24.2806%;" width="141">
<p>JE vaccine</p>
</td>
<td style="width: 33.8129%;" width="274">
<p>Local reaction, low-grade fever, myalgia</p>
</td>
<td style="width: 42.0863%;" width="312">
<p>Neurologic events like encephalitis</p>
</td>
</tr>
<tr>
<td style="width: 24.2806%;" width="141">
<p>Measles/MMR</p>
</td>
<td style="width: 33.8129%;" width="274">
<p>Local reactions, fever, malaise, irritability</p>
</td>
<td style="width: 42.0863%;" width="312">
<p>Febrile seizures, arthralgia, thrombocytopenia</p>
</td>
</tr>
<tr>
<td style="width: 24.2806%;" width="141">
<p>Yellow fever</p>
</td>
<td style="width: 33.8129%;" width="274">
<p>Headache, flu like symptoms, local reactions</p>
</td>
<td style="width: 42.0863%;" width="312">
<p>Vaccine-associated viscerotropic disease</p>
</td>
</tr>
<tr>
<td style="width: 24.2806%;" width="141">
<p>Oral polio</p>
</td>
<td style="width: 33.8129%;" width="274">
<p>None</p>
</td>
<td style="width: 42.0863%;" width="312">
<p>Vaccine associated paralytic poliomyelitis</p>
</td>
</tr>
<tr>
<td style="width: 24.2806%;" width="141">
<p>DPT</p>
</td>
<td style="width: 33.8129%;" width="274">
<p>Local reaction, fever</p>
</td>
<td style="width: 42.0863%;" width="312">
<p>Neurologic events like encephalitis, seizures, HHE (hypotonic hyporesponsive episode), anaphylaxis, persistent inconsolable screaming</p>
</td>
</tr>
</tbody>
</table>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 10</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>A mother brought her 6-month old infant baby to an Anganwadi worker Lata for advice regarding the vaccination of her child. The last vaccines he had received were OPV3, PENTA 3, IPV2, and ROTA3 at 14 weeks of age. BCG and Hep B were given at birth. When is the next vaccination due?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>MR vaccine at left arm intramuscularly and Vitamin A drops at the end of 9 months</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>MR vaccine at right arm subcutaneously and Vitamin A drops at the end of 8 months</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>MR vaccine at left arm intramuscularly and Vitamin A drops at the end of 8 months</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>MR vaccine at right arm subcutaneously and Vitamin A drops at the end of 9 months</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>According to the <strong>National Immunization Schedule</strong>, the <strong>Measles/MR vaccine</strong> is given at <strong>9 completed months</strong> (1<sup>st</sup> dose), and a second dose is given at <strong>16-24 months</strong>. Measles vaccine can be given till 5 years of age. A dose of <strong>5 mL</strong> is administered subcutaneously in the <strong>right upper arm.</strong></li>
<li><strong>Vitamin A is scheduled</strong> in the National Immunisation Schedule (NIS).</li>
<li><strong>1 lakh IU</strong> at <strong>9 completed months</strong> along with the <strong>Measles-Rubella vaccine</strong></li>
<li><strong>2 lakh IU</strong> is administered bi-annually for children between <strong>1-5 years of age</strong></li>
<li>Total number of doses administered- <strong>9 doses, 17 lakhs IU.</strong></li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 11</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>Although many animals are implicated in the spread of rabies, dogs are the most common ones. Also, it usually affects children in developing countries. Knowing this, what is the most cost-effective and logical way to reduce the incidence of rabies?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Testing all the dogs for rabies</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Reduce stray dog population and vaccinate all dogs</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Increase the laboratory facilities</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Increase capacity of healthcare workers for surveillance</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li><strong>Reducing the stray dog population</strong> and <strong>vaccinating all dogs</strong> is the most cost-effective and logical way to reduce the incidence of rabies. The Animal Birth Control initiative from the Government of India is directed towards this goal.</li>
<li><strong>Rabies</strong> is a highly fatal viral disease caused by <strong>Lyssavirus type 1,</strong> affecting the <strong>central nervous system. Dogs</strong> are considered the major <strong>source</strong> of rabies infection. Thus immunization of dogs at the age of <strong>3-4 months </strong>and booster doses at regular intervals is recommended to control rabies. The type of vaccines used are:</li>
<li><strong>BPL inactivated nervous tissue vaccine</strong> - it is a <strong>single-dose</strong> Booster is advised after <strong>6 months</strong> and subsequently <strong>every year.</strong></li>
<li><strong>Modified live virus vaccine</strong> - it is also a single-dose vaccine and a booster is given <strong>every 3 years</strong>.</li>
</ul>
<p>Other methods to <strong>control rabies</strong> include:</p>
<ul>
<li>Registration and licensing of all domestic dogs</li>
<li>The immediate killing of dogs and cats bitten by rabid animals</li>
<li>6 months&rsquo; quarantine for imported dogs</li>
<li>Educating people regarding dog care and prevention of rabies</li>
</ul>
<p><strong>Note:</strong> <strong>Strengthening laboratory facilities</strong> and <strong>surveillance </strong>are also the methods used to reduce the incidence according to the <strong>National Rabies Control Program (NRCP).</strong></p>
<ul>
<li>Humans get infected after a <strong>deep bite</strong> or <strong>scratch</strong> by an infected animal. The transmission also occurs when the <strong>saliva</strong> of the infected dog comes into direct contact with human mucosa or fresh skin wounds.</li>
<li>Rabies in man is also known as <strong>hydrophobia</strong>. The clinical features usually begin as prodromal symptoms like headache, and fever followed by <strong>neurological symptoms</strong>. The patients usually present with confusion, hallucination, irritability, hydrophobia, <strong>aerophobia</strong>, and muscle spasms. They also present with symptoms of <strong>autonomic dysfunction</strong> such as <strong>hypersalivation</strong>, lacrimation, cardiac arrhythmias, etc.</li>
</ul>
<p><strong>Laboratory tests for rabies include:</strong></p>
<ul>
<li><strong>Fluorescent antibody test</strong> is a highly reliable and best test for rapid detection of rabies antigen in the infected specimens.</li>
<li>Microscopic examination of the brain tissue to demonstrate Negri bodies.</li>
</ul>
<p><strong>Table: Rabies vaccines and immunoglobulins schedules</strong></p>
<p><strong><img title="6.jpg" src="https://static.pw.live/5eb393ee95fab7468a79d189/ADMIN/3610bef8-1a91-40f6-8a28-4fe8499c3479.jpg" alt="" width="403" height="210" /></strong></p>
<p><strong><img title="7.jpg" src="https://static.pw.live/5eb393ee95fab7468a79d189/ADMIN/9575270b-761d-4c0d-b4a0-a63cf286b71d.jpg" alt="" width="228" height="591" /></strong></p>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 12</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>Which of the following is a subunit vaccine?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>BCG vaccine</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Hepatitis B vaccine</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>DPT vaccine</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>IPV vaccine</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li><strong>Hepatitis B</strong> vaccine is an example of a <strong>subunit vaccine</strong> made using</li>
<li>Subunit vaccines are produced from macromolecules derived from immunogenic components of organisms by <strong>recombinant DNA technology</strong>. E.g., <strong>HPV vaccine</strong> (uses <strong>L1 major capsid protein</strong>) and hepatitis B vaccine (uses HBsAg).</li>
<li>BCG is a live attenuated vaccine, IPV is an inactivated vaccine and DPT has diphtheria and tetanus toxoids and a killed pertussis component.</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 13</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>An auxiliary nurse midwife has to conduct a vaccination camp in a village. She received 2 open vials, one of which is a pentavalent vaccine and the other is an MR vaccine. What can she do regarding the utilization of these vials?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Use MR vaccine and discard pentavalent vaccine</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Use pentavalent vaccine and discard MR vaccine</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Use both</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Discard both</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>She can use the <strong>pentavalent vaccine</strong> and <strong>discard</strong> the <strong>MR vaccine</strong>. According to the <strong>open vial policy</strong>, the pentavalent vaccine can be reused, whereas MR cannot be reused.</li>
<li>Open vial policy was implemented to allow the reuse of partially used <strong>multidose vials</strong> under the Universal Immunization Program (UIP) for up to <strong>28 days</strong> if certain conditions are met. This was implemented to <strong>reduce vaccine wastage</strong>.</li>
<li>It applies only to DPT, TT, hepatitis B, oral polio vaccine (OPV), <strong>liquid pentavalent</strong>, PCV, injectable IPV, inactivated Japanese encephalitis (JE) vaccine, and rotavirus vaccine. It does not apply to <strong>Measles/MR</strong> and BCG vaccines.</li>
</ul>
<p><strong>Note:</strong> <strong>Open vial policy</strong> does not apply to rotavirus vaccine with VVM on cap, it applies <strong>only to new</strong> rotavirus vaccine with <strong>VVM on label. &nbsp;&nbsp;</strong></p>
<p><strong>Open Vial Policy</strong></p>
<ul>
<li>Open vial policy allows for reuse of partially used <strong>multidose vials</strong> of applicable vaccines under the Universal Immunization Programme in subsequent sessions up to <strong>4 weeks (28 days)<sup> Q</sup></strong> subject to certain conditions and thereby reducing vaccine wastage.</li>
<li>It is applicable only for <strong>DPT, TT, hepatitis B vaccine, OPV, liquid pentavalent vaccine, rotavirus vaccine<sup>Q</sup> (new version with the VVM on the side),</strong> and <strong>JE vaccines (inactivated).</strong> It is not applicable <strong>to BCG and measles vaccines</strong><sup>Q</sup>.</li>
<li>Vaccine vials opened in session-site can be used in more than one session up to four weeks if <strong>expiry date has not passed</strong>, <strong>if storage and transport was appropriate, no contamination has occurred in vial septum, asepsis in withdrawing was practiced and if vaccine vial monitor has not reached discard point</strong>.</li>
<li>Open vials should <strong>not</strong> be submerged in water. All open vials should have a record of <strong>date and time of opening</strong>. At the end of a session, all vaccines should be returned to the cold chain point and segregated as re-usable and non-reusable. All open vials of BCG, measles must be destroyed after 48 hours or before next session, whichever is earlier.</li>
<li>In case of any <strong>adverse events following immunization</strong>, all open vials should not be discarded until investigation is complete. All vials must be transported in zipper bags in the vaccine carrier and recorded in stock register. Ice packs used should be well sealed.</li>
</ul>
<p><strong>Recent Update </strong></p>
<p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Updated Rotavac with open vial policy </u></strong></p>
<ul>
<li>MOHFW has updated VVM guidelines on the <strong>oral Rotavac</strong> vaccine to change the <strong>location of the Vaccine Vial Monitor</strong>, which was initially on the cap of the vial, <strong>to the label</strong> of the vaccine vial.</li>
<li>The <strong>open multi-dose policy</strong> is applicable <strong>only </strong>to this <strong>new presentation</strong> of the vaccine. Implementation of the Open Vial Policy allows the reuse of partially used multi-dose vials of applicable vaccines under the universal immunization policy to prevent wastage of medication.</li>
<li>The vaccine schedule will remain the same, that is a <strong>3-dose schedule</strong> at 6 weeks, 10 weeks, and 14 weeks. It is to be stored at -<strong>50&deg;C to -25&deg;C</strong> till district stores and then at <strong>2&deg;C to 8&deg;C</strong> at the <strong>sub-district</strong></li>
</ul>
<p><strong><img title="8.jpg" src="https://static.pw.live/5eb393ee95fab7468a79d189/ADMIN/c7045f4d-59f2-4c1e-ad67-957fe6e0a766.jpg" alt="" width="312" height="205" /></strong></p>
<p><strong>Vaccine Vail Monitor (VVM)</strong></p>
<ul>
<li>Vaccine Vial Monitoring (VVM) is a label containing a heat-sensitive material placed on a vaccine vial. It registers <strong>cumulative heat exposure<sup>Q</sup></strong> over time.</li>
<li>If the color of the <strong>inner square</strong> is the <strong>same color or darker</strong> than the <strong>outer circle</strong>, it indicated that the vaccine has been exposed to too much heat and it must be</li>
<li>Currently, there are <strong>four types</strong> of VVMs (VVM2, VVM7, VVM14 and VVM30). They are chosen to match the heat sensitivity of the vaccine.</li>
<li>The VVM can be located on the label of the vaccine or on the neck or cap of the ampule/vial.</li>
<li>VVMs also help in <strong>reduction of vaccine wastage</strong> by indicating which batch of vaccine can be used first.</li>
</ul>
<p><img title="9.png" src="https://static.pw.live/5eb393ee95fab7468a79d189/ADMIN/be0ebba3-b6f1-4497-b347-1cfef7235f73.png" alt="" width="400" height="176" /></p>
<p><strong><u>Stages of VVM</u></strong></p>
<table style="border-collapse: collapse; width: 90.1257%; height: 312px;" border="1">
<tbody>
<tr>
<td style="width: 23.9209%;" width="147">
<p>Stage 1</p>
</td>
<td style="width: 76.0791%;" width="559">
<p>The inner square is lighter than the outer circle</p>
</td>
</tr>
<tr>
<td style="width: 23.9209%;" width="147">
<p>Stage 2</p>
</td>
<td style="width: 76.0791%;" width="559">
<p>The inner square is still lighter than the outer circle</p>
</td>
</tr>
<tr>
<td style="width: 23.9209%;" width="147">
<p>Stage 3- Discard Point</p>
</td>
<td style="width: 76.0791%;" width="559">
<p>The color of the inner square matches that of the outer circle. <strong>Vaccine should not be used</strong>.</p>
</td>
</tr>
<tr>
<td style="width: 23.9209%;" width="147">
<p>Stage 4-Beyond the Discard Point</p>
</td>
<td style="width: 76.0791%;" width="559">
<p>The color of the inner square is darker than the outer circle. <strong>Vaccine should not be used. </strong></p>
</td>
</tr>
</tbody>
</table>
<p>Stage 1 and 2&rsquo; vaccine can be used, if the expiry date has not passed.</p>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 14</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong><strong>Given below is a list of equipment used for the cold storage of vaccines. Arrange the cold storage equipment in the correct order of usage, starting from the primary health center level to the national level.</strong></strong></p>
<ol>
<li>Walk-in-freezers</li>
<li>Walk-in-coolers</li>
<li>Deep freezer</li>
<li>Ice lined refrigerators</li>
</ol>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>3-4-1-2</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>4-3-2-1</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>1-2-3-4</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>4-2-1-3</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>The cold chain equipments that are used at various healthcare strata starting from the primary health center to the national level are <strong>4-3-2-1</strong>e<strong>. ice lined refrigerators &rarr; deep freezer &rarr; walk-in-coolers &rarr; walk-in-freezers.</strong></li>
<li><strong>Ice-lined refrigerators (ILRs)</strong> are similar to conventional refrigerators and are lined with ice packs or tubes. They are categorized based on the vaccine storage capacity. Smaller ones are supplied to the <strong>primary health center (PHC)</strong> headquarters, while larger ones are supplied to district headquarters. They maintain a temperature of <strong>2-8&deg; Celsius</strong> for the storage of vaccines. They have different <strong>temperature zones</strong> for different vaccines and they are stored accordingly in the <strong>baskets</strong> that are provided in most ILRs.</li>
<li><strong>Deep freezer (DF</strong>) is also similar to a conventional refrigerator but has a <strong>top-opening</strong> It maintains a temperature of -<strong>15&deg; to -25&deg; Celsius</strong>. It is used at the <strong>district level</strong> and above for the storage of oral polio vaccines for 3 months. At the <strong>sub-district level</strong>, it is used for freezing icepacks.</li>
<li><strong>Walk-in-coolers (WIC)</strong> are insulated cold rooms with two cooling units with an uninterrupted power supply. They maintain a temperature of <strong>2-8&deg; Celsius</strong>. They are used at government medical store depots, <strong>state, regional</strong>, and occasionally <strong>district </strong>level vaccine stores.</li>
<li><strong>Walk-in-freezers (WIF)</strong> are similar to WIC but maintain a temperature of -<strong>15&deg; to -25&deg; Celsius</strong>. They are used at <strong>national,</strong> state, and regional vaccine stores.</li>
</ul>
<p><img title="Q.jpg" src="https://static.pw.live/5eb393ee95fab7468a79d189/ADMIN/1158feb2-577f-42a0-946f-f171952cbbba.jpg" alt="" width="350" height="360" /></p>
<p><strong>Table: Electrical Cold Chain Equipment</strong></p>
<table style="border-collapse: collapse; width: 100%;" border="1">
<tbody>
<tr>
<td style="width: 25.3597%;" width="179">
<p><strong>Component</strong></p>
</td>
<td style="width: 21.5827%;" width="123">
<p><strong>Temperature (Degree Celsius)</strong></p>
</td>
<td style="width: 27.8777%;" width="221">
<p><strong>Level</strong></p>
</td>
<td style="width: 25.1799%;" width="174">
<p><strong>Other Comments</strong></p>
</td>
</tr>
<tr>
<td style="width: 25.3597%;" width="179">
<p>Walk in Freezers (WIF)</p>
</td>
<td style="width: 21.5827%;" width="123">
<p>-15 to -25</p>
</td>
<td style="width: 27.8777%;" width="221">
<p>National, State and Regional vaccine stores</p>
</td>
<td style="width: 25.1799%;" width="174">
<p>Used for bulk storage of <strong>OPV</strong></p>
</td>
</tr>
<tr>
<td style="width: 25.3597%;" width="179">
<p>Walk in Coolers (WIC)</p>
</td>
<td style="width: 21.5827%;" width="123">
<p>+2 to +8</p>
</td>
<td style="width: 27.8777%;" width="221">
<p>Government Medical Store Depot (GMSD), State and Regional vaccines stores</p>
</td>
<td style="width: 25.1799%;" width="174">
<p>Used for bulk storage of most vaccines in UIP</p>
</td>
</tr>
<tr>
<td style="width: 25.3597%;" width="179">
<p>Deep Freezer (DF)</p>
</td>
<td style="width: 21.5827%;" width="123">
<p>-15 to -25</p>
</td>
<td style="width: 27.8777%;" width="221">
<p>District and Sub-district vaccines stores</p>
</td>
<td style="width: 25.1799%;" width="174">
<p>Used for bulk storage of <strong>OPV</strong> and ice packs</p>
</td>
</tr>
<tr>
<td style="width: 25.3597%;" width="179">
<p><strong>Ice Line Refrigerator (ILR)<sup>Q</sup></strong></p>
</td>
<td style="width: 21.5827%;" width="123">
<p><strong>+2 to +8<sup>Q</sup></strong></p>
</td>
<td style="width: 27.8777%;" width="221">
<p>District and Sub-district vaccines stores, <strong>PHCs<sup>Q</sup></strong></p>
</td>
<td style="width: 25.1799%;" width="174">
<p>Has different <strong>temperature zones</strong><sup>Q</sup> for different vaccines</p>
</td>
</tr>
<tr>
<td style="width: 25.3597%;" width="179">
<p>Front Load Refrigerator (Domestic)</p>
</td>
<td style="width: 21.5827%;" width="123">
<p>+2 to +8</p>
</td>
<td style="width: 27.8777%;" width="221">
<p>Sub-district levels, hospitals. dispensaries and nursing homes</p>
</td>
<td style="width: 25.1799%;" width="174">
<p>Used for all vaccines</p>
</td>
</tr>
</tbody>
</table>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 15</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>You should perform a shake test prior to using all of the following vaccines, except:</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>OPV</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>TT</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>IPV</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Hep B</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>Only the <strong>injectable</strong> polio vaccine (IPV) is <strong>freeze sensitive, not the oral</strong> polio vaccine (OPV). Hence, a shake test is not relevant for OPV.</li>
<li>The <strong>shake test</strong> is done to check for <strong>damage</strong> to vaccines that are sensitive to <strong>freezing temperatures</strong>.</li>
</ul>
<p><strong>Steps to perform the shake test:</strong></p>
<ul>
<li>A <strong>frozen vaccine</strong> is used as a <strong>control vial,</strong> and the vial suspected to be damaged by freezing is taken as the test vial.</li>
<li>Both are <strong>shaken after thawing</strong>, and the rate of <strong>sedimentation</strong> is</li>
<li>If the rate of <strong>sedimentation</strong> in the test vial is <strong>slower than</strong> that in the <strong>control</strong> vial, then it is <strong>usable </strong>and has not been damaged.</li>
</ul>
<p><img title="11.png" src="https://static.pw.live/5eb393ee95fab7468a79d189/ADMIN/bf9fc5aa-eb73-447c-87ab-7ddcdb36a571.png" alt="" width="350" height="385" /></p>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 16</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>A 24-year-old pregnant woman comes to you in her first trimester and asks for your advice regarding immunisation. Which of the following vaccines would you pick that is contraindicated for her?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Hepatitis A vaccine</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Hepatitis B vaccine</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Tetanus toxoid</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Varicella vaccine</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li><strong>Varicella vaccine</strong> is c<strong>ontraindicated</strong> for her as she is</li>
<li>Varicella vaccine is a <strong>live attenuated</strong> vaccine which is recommended for <strong>children </strong>aged <strong>12-18 months</strong> and those without a history of chickenpox infection in the past. It is administered <strong>subcutaneously</strong> in one or two-dose schedules.</li>
<li>It is contraindicated in <strong>pregnant, immunocompromised</strong> individuals and those who are <strong>allergic</strong> to <strong>neomycin</strong>. However, patients with clinically stable HIV on HAART (highly active anti-retroviral therapy) can be considered for vaccination if CD4+ cells &gt;15%. Avoidance of <strong>salicylates</strong> is recommended <strong>6 weeks</strong> after the vaccination to prevent <strong>Reye's syndrome</strong>.</li>
<li>Maternal varicella infection may result in <strong>fetal loss</strong> and <strong>birth defects</strong>. If maternal varicella infection occurs within <strong>5 days of delivery</strong>, the baby should receive <strong>VZIG</strong> (varicella-zoster immunoglobulin) due to the risk of disseminated infection.</li>
</ul>
<p><strong>Other options: </strong></p>
<ul>
<li><strong>Options A:</strong> <strong>Hepatitis A vaccine</strong> can be administered as pre-exposure or post-exposure prophylaxis in <strong>high-risk pregnant</strong> individuals in a two-dose schedule is given <strong>intramuscularly </strong>one month apart.</li>
<li><strong>Option B: Hepatitis B vaccine </strong>can be administered as pre-exposure or post-exposure prophylaxis in <strong>high-risk pregnant</strong> It is given <strong>intramuscularly </strong>in three doses at 0, 1, and 6 months.</li>
<li><strong>Option C: Tetanus toxoid</strong> is routinely administered in pregnant women. The <strong>first dose</strong> is given at <strong>16-20 weeks </strong>while the <strong>second dose</strong> is at <strong>20-24 weeks</strong> ideally maintaining a one-month interval between the two doses.</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 17</h3>
                <p><b>A child has come to you for the administration of the IPV vaccine, as part of his routine immunisation schedule. Which of the following antibiotics may be found in this vaccine?</p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. Penicillin</li><li>2. Streptomycin</li><li>3. Amikacin</li><li>4. Erythromycin</li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><ul ><li>IPV may contain trace amounts of streptomycin, neomycin or polymyxin B.</li><li>MMR contain small amount of neomycin.</li><li>Antibiotics are used during vaccine manufacture to prevent bacterial contamination of tissue culture cells.</li></ul></li></ul></div></div>
            <div class="question">
                <h3>Question No: 18</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>Which of the following vaccine is most sensitive to heat?</strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Japanese encephalitis vaccine</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Measles vaccine</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Oral polio vaccine</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>Pentavalent vaccine</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>Oral Polio Vaccine is the most heat-sensitive vaccine. Hence, it is kept in the lower zone of the Ice Lined Refrigerator.</li>
</ul>
<p><strong> Flowchart:</strong> Thermosensitivity of Vaccine</p>
<p><img title="12.jpg" src="https://static.pw.live/5eb393ee95fab7468a79d189/ADMIN/dcdb11f9-4ecd-4f23-9728-98d3d07b62e1.jpg" alt="" width="185" height="262" /> <img title="13.jpg" src="https://static.pw.live/5eb393ee95fab7468a79d189/ADMIN/8a8ce5eb-a7fb-451e-9183-c397d21263e9.jpg" alt="" width="288" height="350" /></p>
<ul>
<li><strong>Vaccine sensitivity to heat:</strong> BCG (after reconstruction- Most sensitive) &gt; OPV &gt; Measles &gt; DPT &gt; BCG (Before reconstruction) &gt; DT &gt; TT &gt; Hepatitis B &gt; JE (Least sensitive). &nbsp;</li>
<li><strong>Light sensitive vaccines:</strong> <strong>BCG, Measles<sup>Q</sup></strong>. So, these are supplied in <strong>amber-colored<sup>Q</sup></strong></li>
<li><strong>Vaccine sensitive to freezing:</strong> Hepatitis B (Most) &gt; Pentavalent &gt; DPT &gt; DT &gt; TT (Least). &nbsp;</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 19</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong><strong>A 20-day-old child who was not vaccinated at birth was brought to the OPD for vaccination. Which of the following vaccines can be administered to this child?</strong></strong></p>
<ol>
<li>BCG</li>
<li>OPV-0</li>
<li>HEP-B</li>
</ol>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>1,2</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>1,3</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>1</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>1,2,3</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>The vaccine that can be administered to a 20-day-old child who was not vaccinated at birth is BCG.</li>
<li>The vaccines that are administered at birth are BCG, OPV-0, HEP-B
<ul>
<li>BCG can be administered till 1 year of age</li>
<li>OPV-0 should be administered within 15 days after birth</li>
<li>HEP-B should be administered within 24 hours after birth.</li>
</ul>
</li>
</ul>
</body>
</html></li></ul></div></div>
            <div class="question">
                <h3>Question No: 20</h3>
                <p><!DOCTYPE html>
<html>
<head>
</head>
<body>
<p><strong>Identify the correct statement about the information obtained from the vaccine vial monitor 14 (VVM14) shown in the image below.</strong></p>
<p><strong><img title="SD.jpg" src="https://static.pw.live/5eb393ee95fab7468a79d189/ADMIN/36ef5b6c-957b-4b1f-b86a-734f617fbe01.jpg" alt="" width="130" height="256" /></strong></p>
</body>
</html></p>
                <div class="options">
                    <h4>Options:</h4>
                    <ul>
            <li>1. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>It takes 14 days for the inner square to become darker than outer circle</p>
</body>
</html></li><li>2. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>It takes 14 days for the inner square and outer circle to reach the same color</p>
</body>
</html></li><li>3. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>The vaccine can be used for 14 days after the inner square and outer circle reach the same color</p>
</body>
</html></li><li>4. <!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>The vaccine can be used for 14 days after the outer circle color becomes darker</p>
</body>
</html></li></ul></div><div class="solution"><h4>Solution:</h4><ul><li><!DOCTYPE html>
<html>
<head>
</head>
<body>
<ul>
<li>The given scenario mentions <strong>VVM 14</strong> (vaccine vial monitor 14), where <strong>14 </strong>indicates the <strong>VVM number</strong>. It is the <strong>time in days</strong> for the <strong>inner square</strong> to reach the <strong>color of the outer circle</strong> when the vial is exposed to a constant temperature of 37&deg;C. This color change signifies the <strong>discard point</strong> of the vial.</li>
<li><strong>Vaccine Vial Monitors (VVM)</strong> are heat-sensitive indicators that are routinely used to monitor vaccine viability as the vaccine vial moves across the supply chain. It records <strong>cumulative heat exposure</strong> through a <strong>gradual change in color.</strong></li>
<li>There are currently 4 types of VMs, they are chosen to match the <strong>heat sensitivity</strong> of the vaccines based on the VM number.</li>
<li>VVM 30: High Stability</li>
<li>VVM 14: Medium Stability</li>
<li>VVM 7: Moderate Stability</li>
<li>VVM 2: Least Stable</li>
</ul>
<p>If the color of the <strong>inner square</strong> is the <strong>same </strong>or is <strong>darker than the outer circle</strong>, it indicates that the vaccine has been exposed to high temperatures and should be <strong>discarded.</strong></p>
<p><strong>Purpose of VVMs</strong>:</p>
<ul>
<li>Ensures that vaccines <strong>damaged by heat</strong> are not administered</li>
<li>Decision on which vaccines to be kept after a <strong>cold chain break occurs</strong>, minimizing unnecessary vaccine wastage</li>
<li>Decision on which <strong>vaccine</strong> is <strong>to be used first</strong>. Vaccines showing significant heat exposure should be used before those that show lower heat exposure, even if their expiry date is longer.</li>
</ul>
<p>There are two different locations for VVMs:</p>
<ul>
<li><strong>On the label</strong> of the vaccine: The vaccine vial, once opened, can be kept for subsequent immunization sessions for <strong>up to 28 days</strong>, regardless of the formulation of the product.</li>
<li>In a location <strong>other than on the label</strong> (e.g., cap or neck of ampoule): The vaccine vial, once opened should be discarded at the end of the immunization session or <strong>within six hours of opening</strong>, whichever comes first, regardless of the formulation of the product.</li>
</ul>
</body>
</html></li></ul></div></div>
        <div class="credits">
            <p class="rainbow-text">Credit: Code Written by BHASKAR</p>
        </div>
        </body></html>